Yarrow Bioscience Inc (YARW) FinancialsYARWYarrow Bioscience Inc

Evaluating the bottom line, Yarrow Bioscience, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3197.94%, while the net margin is -2988.66%. These profitability ratios, combined with a Return on Equity (ROE) of -61.93%, provide a clear picture of how effectively YARW converts its operational activities into shareholder value.

In the context of the broader market, YARW competes directly with industry leaders such as ADCT and AKBA. With a market capitalization of $114.78M, it holds a significant position in the sector. When comparing efficiency, YARW's gross margin of 100.00% stands against ADCT's 88.68% and AKBA's 80.50%. Such benchmarking helps identify whether Yarrow Bioscience, Inc. is trading at a premium or discount relative to its financial performance.

Yarrow Bioscience has shown a gross margin of 100% across recent quarters, but it has also reported increasing net income losses, with the latest loss at $3,007,000 in Q2 2026. The company's current ratio is strong at 15.26, indicating good liquidity.